Literature DB >> 27354720

Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Armin Rashidi1, Roland B Walter2, Martin S Tallman3, Frederick R Appelbaum4, John F DiPersio1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27354720      PMCID： PMC4982451          DOI： 10.1182/blood-2016-03-674127

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  72 in total

1.  Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.

Authors:  D Blaise; M Attal; J Reiffers; M Michallet; C Bellanger; J L Pico; A M Stoppa; C Payen; G Marit; R Bouabdallah; J J Sotto; J F Rossi; M Brandely; T Hercend; D Maraninchi
Journal:  Eur Cytokine Netw       Date:  2000-03       Impact factor: 2.737

2.  Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.

Authors:  T Büchner; W Hiddemann; B Wörmann; H Löffler; G Maschmeyer; D Hossfeld; W D Ludwig; M Nowrousian; C Aul; U W Schaefer
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

3.  A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

Authors:  Shuichi Miyawaki; Hisashi Sakamaki; Shigeki Ohtake; Nobuhiko Emi; Fumiharu Yagasaki; Kinuko Mitani; Shin Matsuda; Yuji Kishimoto; Yasushi Miyazaki; Norio Asou; Takafumi Matsushima; Masatomo Takahashi; Yoshiaki Ogawa; Sumihisa Honda; Ryuzo Ohno
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

4.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

Authors:  A H Goldstone; A K Burnett; K Wheatley; A G Smith; R M Hutchinson; R E Clark
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Varying intensity of postremission therapy in acute myeloid leukemia.

Authors:  P A Cassileth; E Lynch; J D Hines; M M Oken; J J Mazza; J M Bennett; P B McGlave; M Edelstein; D P Harrington; M J O'Connell
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

6.  A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.

Authors:  U Jehn; R Zittoun; S Suciu; D Fiere; C Haanen; M Peetermans; B Löwenberg; R Willemze; G Solbu; P Stryckmans
Journal:  Haematol Blood Transfus       Date:  1990

7.  Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.

Authors:  F S Morrison; K J Kopecky; D R Head; J W Athens; S P Balcerzak; C Gumbart; L Dabich; J J Costanzi; C A Coltman; J H Saiki
Journal:  Leukemia       Date:  1992-07       Impact factor: 11.528

8.  6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Authors:  Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert L Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Maintenance therapy in childhood acute myeloid leukemia.

Authors:  Y Perel; A Auvrignon; T Leblanc; G Michel; J P Vannier; J H Dalle; V Gandemer; C Schmitt; F Mèchinaud; J P Lamagnere; Ch Piguet; G Couillaud; B Pautard; A Baruchel; G Leverger
Journal:  Ann Hematol       Date:  2004       Impact factor: 3.673

10.  Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

Authors:  Mats Brune; Sylvie Castaigne; John Catalano; Kurt Gehlsen; Anthony D Ho; Wolf-Karsten Hofmann; Donna E Hogge; Bo Nilsson; Reuven Or; Ana I Romero; Jacob M Rowe; Bengt Simonsson; Ruth Spearing; Edward A Stadtmauer; Jeff Szer; Elisabeth Wallhult; Kristoffer Hellstrand
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113
View more
  14 in total

1.  FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Authors:  Mark J Levis; Yi-Bin Chen; Mehdi Hamadani; Mary M Horowitz; Richard J Jones
Journal:  J Clin Oncol       Date:  2019-04-29       Impact factor: 44.544

Review 2.  New Treatment Options for Acute Myeloid Leukemia in 2019.

Authors:  Marco Cerrano; Raphael Itzykson
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 3.  Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.

Authors:  Frederick R Appelbaum
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

Review 4.  Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

5.  Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.

Authors:  Qiang Zeng; Zhigang Liu; Bing Xiang
Journal:  Ann Hematol       Date:  2022-05-16       Impact factor: 4.030

Review 6.  Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Authors:  Bruno C Medeiros; Steven M Chan; Naval G Daver; Brian A Jonas; Daniel A Pollyea
Journal:  Am J Hematol       Date:  2019-05-01       Impact factor: 10.047

7.  The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.

Authors:  Michael M Boyiadzis; Ivan Aksentijevich; Daniel A Arber; John Barrett; Renier J Brentjens; Jill Brufsky; Jorge Cortes; Marcos De Lima; Stephen J Forman; Ephraim J Fuchs; Linda J Fukas; Steven D Gore; Mark R Litzow; Jeffrey S Miller; John M Pagel; Edmund K Waller; Martin S Tallman
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

8.  Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

Authors:  Patrick K Reville; Hagop M Kantarjian; Farhad Ravandi; Elias Jabbour; Courtney D DiNardo; Naval Daver; Naveen Pemmaraju; Maro Ohanian; Yesid Alvarado; Lianchun Xiao; Gheath Alatrash; Sanam Loghavi; Caitlin R Rausch; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Tapan M Kadia
Journal:  Blood Cancer J       Date:  2021-03-17       Impact factor: 11.037

Review 9.  Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.

Authors:  Steven D Green; Heiko Konig
Journal:  Front Genet       Date:  2020-05-27       Impact factor: 4.599

10.  Prospective evaluation of clinical symptoms of chemotherapy-induced oral mucositis in adult patients with acute leukemia: A preliminary study.

Authors:  Yeon-Hee Lee; Junshik Hong; Inho Kim; Youngnim Choi; Hee-Kyung Park
Journal:  Clin Exp Dent Res       Date:  2019-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.